Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) maintains this comprehensive news hub for investors tracking developments in its clinical-stage cancer therapeutics. Our curated collection features official press releases, regulatory filings, and material event announcements related to the company’s protein phosphatase inhibitor pipeline.
This resource enables stakeholders to monitor critical updates including clinical trial progress for lead compound LB-100, financial disclosures, and strategic collaborations. All content is sourced directly from company communications and SEC filings to ensure reliability.
Key categories include Phase 1/2 trial results, intellectual property milestones, executive leadership changes, and quarterly earnings reports. Bookmark this page for timely access to investment-relevant developments in Lixte’s novel approach to enhancing chemotherapy and radiation efficacy through targeted phosphatase inhibition.
LIXTE (Nasdaq: LIXT) announced an expansion of its ongoing ovarian clear cell cancer trial combining its compound LB-100 with GSK's dostarlimab. The study, initiated in January 2024, will double enrollment from 21 to 42 patients across two sites: MD Anderson and the Robert H. Lurie Comprehensive Cancer Center at Northwestern. The trial is led by Amir Jazaeri, MD, and Emily M. Hinchcliff, MD, MPH. LIXTE expects initial data from the first 21 patients to be presented in the first half of 2026. The company framed the expansion as progress toward evaluating LB-100’s potential to enhance immunotherapy and chemotherapy outcomes.
Lixte Biotechnology (NASDAQ: LIXT) entered definitive agreements for a registered direct offering to raise approximately $4.3 million by selling 1,051,342 Common Units (or Pre-Funded Units) at a public offering price of $4.09 per Common Unit (or $4.08999 per Pre-Funded Unit). Each unit includes one share or one pre-funded warrant plus one common warrant exercisable at $3.96 and expiring 60 months after issuance. Pre-Funded Warrants are immediately exercisable. The offering is priced at the market under Nasdaq rules and is expected to close on or about December 19, 2025. Proceeds are intended for general corporate purposes and working capital.
Spartan Capital Securities is exclusive placement agent; offering made from an effective Form S-3 shelf (declared effective May 2, 2024).
LIXTE (NASDAQ:LIXT) is broadening its oncology strategy by acquiring Liora Technologies and adding the LiGHT System radiotherapy platform, signaling a shift from a single‑asset biotech toward a multi‑modal oncology company.
The move (announced December 8, 2025) pairs LIXTE's clinical‑stage drug LB‑100—a PP2A inhibitor that sensitizes tumors to stress—with a smaller‑footprint proton radiotherapy system, enabling potential drug‑device combinations and more direct clinical evaluation.
LIXTE (NASDAQ:LIXT) is advancing its lead clinical-stage PP2A inhibitor LB-100 and shifting toward a multi-modal oncology platform as of December 3, 2025. Key developments include active collaborations testing LB-100 with dostarlimab (GSK) and atezolizumab (Roche), a temporary safety pause in the metastatic microsatellite-stable colon-cancer combo trial, and prior Phase 1 tolerability data in soft-tissue sarcoma. Strategically, LIXTE announced the acquisition of Liora Technologies Europe Ltd. (LiGHT proton therapy system) and reported converting about $2.6 million of treasury into digital/convertible assets, part of talks to acquire complementary oncology assets to broaden its pipeline.
Those moves expand LIXTE from a single‑asset biotech toward a diversified science and infrastructure strategy combining drugs, radiation hardware, and balance-sheet flexibility.
LIXTE Biotechnology (NASDAQ:LIXT) on December 3, 2025 outlined progress for its PP2A inhibitor LB-100, positioning the drug as an "amplifier" to boost chemo, radiation, and immunotherapy.
Key points: Phase 1 tolerability reported with no toxicity concerns; partnerships with GSK (dostarlimab, full funding for ovarian program) and Roche (atezolizumab, full funding for colorectal study); enrollment finished in a Phase 1b soft-tissue sarcoma trial but further development there is paused to focus on combinations. Company also restored Nasdaq compliance and added digital assets to its treasury.
LIXTE Biotechnology (Nasdaq: LIXT) completed the acquisition of UK-based Liora Technologies Europe Ltd. on November 25, 2025, making Liora a wholly owned subsidiary and adding the proprietary LiGHT System (Linac for Image Guided Hadron Therapy) to LIXTE’s assets.
The LiGHT System is installed at STFC’s Daresbury Laboratory, where STFC will provide resources to develop a center of excellence. The release notes $300+ million invested to date in developing the technology and describes LIXTE’s plan to pursue a recurring revenue model through jointly operated treatment centers while complementing ongoing LB-100 clinical trials.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced that CEO Geordan Pursglove will present at the Spartan Capital Investor Conference 2025 in New York on November 3, 2025 at 4:00 PM ET. Management will also hold one-on-one investor meetings during the conference.
The event is at the Marriott Marquis, 1535 Broadway. Investors can register or schedule meetings via the conference website at https://spartancapital.com/spartan-capital-investor-conference-2025/.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) on Oct 16, 2025 outlined Q4 priorities centered on advancing its lead candidate LB-100 and pursuing oncology-focused business development. The company said it is continuing clinical and preclinical work on LB-100 across prioritized tumor settings and maintaining collaborations with research centers.
LIXTE confirmed it is in advanced negotiations for potential acquisitions of complementary oncology assets to build a multi-asset platform, while noting no assurance any transaction will close. Operational readiness initiatives in quality, CMC, and regulatory alignment were highlighted to support study conduct and potential integration.
LIXTE Biotechnology (NASDAQ:LIXT) is advancing LB-100, a unique clinical-stage inhibitor of protein phosphatase 2A (PP2A) for cancer treatment. The compound works by disabling cancer's survival mechanisms and making tumors more vulnerable to existing therapies.
The company has secured notable partnerships with GSK and Roche to study LB-100 in combination with immunotherapies for ovarian clear-cell carcinoma and microsatellite stable colorectal cancer. While the colorectal study is under a temporary safety pause, Phase 1 data in soft-tissue sarcoma showed promising tolerability.
LIXTE recently made a strategic $2.6 million investment in digital assets, representing nearly half of its treasury, and appointed new leadership including a CFO and board members to strengthen its operational capabilities.
LIXTE Biotechnology (NASDAQ:LIXT) has undergone significant transformation in Summer 2025, marked by key strategic changes. The company implemented major leadership updates, including appointing Geordan Pursglove as Chairman and CEO and repositioning Bas van der Baan as Chief Scientific Officer. LIXTE secured a $5 million private placement in July, regaining Nasdaq compliance.
Scientific validation came through a Nature publication confirming LB-100's efficacy in patients with PPP2R1A mutations, while a new collaboration with the Netherlands Cancer Institute explores preventive applications. The company made headlines by diversifying its treasury with a $2.6 million investment in digital assets, representing an innovative approach to balance sheet management.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXT)?
What is the market cap of Lixte Biotechnology Hldgs (LIXT)?
